It is now recognized that human milk oligosaccharides (HMOs) can function both as prebiotics and as decoy receptors that inhibit the attachment of pathogenic microorganisms to the colonic mucosa. They can also act as immune modulators and as colonic maturation stimulators in breast-fed infants. These functions could be mediated by biological interaction between a variety of HMOs and lectins including galectins, selectins and siglecs. There are more than 100 HMOs; they have structural units such as H type 1: Fucα1-2Galβ1-3GlcNAc, Lewis a: Galβ1-3(Fucα1-4)GlcNAc, Lewis b: Fucα1-2Galβ1-3(Fucα1-4)GlcNAc, Lewis x: Galβ1-4(Fuc α1-3)GlcNAc, sialyl Lewis a: Neu5Acα2-3Galβ1-3(Fucα1-4)GlcNAc, and sialyl Lewis x: Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAc. It can be expected that these units may be utilized as tools for studies on the sugar-binding specificities of lectins including galectins, monoclonal antibodies, virus capsid proteins and bacterial toxins. This mini-review presents the dataset of comprehensive HMO structures, including recently clarified ones, in tabular form, for its utilization in such studies, including those of carbohydratebinding specificity of galectins. In addition, this review introduces recent in vivo and clinical studies, which may be relevant to the biological functions and future utilization of HMOs.
A. Introduction
Human milk contains around 60 g/L of lactose (Galβ1-4Glc), as well as 12-13 g/L of a variety of milk oligosaccharides in mature milk and 22-24 g/L in colostrum. Whereas human milk oligosaccharides (HMOs) comprise several monosaccharide components, such as glucose (Glc), N-acetylglucosamine (GlcNAc), galactose (Gal), fucose (Fuc) and N-acetylneuraminic acid (Neu5Ac), they always have a lactose unit at their reducing ends.
Although by 2009 the structures of about 115 HMOs had been characterized and clarified based on 13 core series (1, 2), a comprehensive database, including large novel structures, had not been described.
When breast-fed infants consume their mother's milk, the majority of the HMOs are not digested and absorbed within the small intestine and therefore reach the infant's colon. It has been suggested from in vitro studies that the HMOs function as prebiotics and decoy receptors, inhibiting the attachment of certain types of pathogenic microorganisms to the colonic mucosa, and as modulators of colonic epithelial maturation (1, (3) (4) (5) . It has been also shown that some strains of Bifidobacterium bifidum, B. longum ssp. infantis, and B. breve are able to grow in medium containing HMOs as the only carbon source (6) (7) (8) . It has been also clarified that B. bifidum is characterized by a unique metabolic pathway in which HMOs are digested by several extracellular and intracellular glycosidases (7) . Notably, low concentrations of some HMOs are detected in plasma from venous blood after the consumption of breast milk (9, 10) . Thus, it appears that a minor part of HMOs is absorbed within the small intestine and enters the circulation. It is possible that those HMOs have immune modulation effects such as anti-inflammation, as suggested by in vitro studies using blood leukocytes (11) , platelets and endothelial cells (12) . It can be as- (Article for special issue on Galectins) CFG symbols are used to express individual monosaccharides with different colors, whereas different glycosidic linkages are shown by different bond angles in a clockwise format; i.e., 1-2 linkage (6:00 O'clock), 1-3 (7:30), 1-4 (9:00), and 1-6 (10:30) . On the other hand, α and β anomers are represented by thin and thick lines, respectively. In the right 'glycotope' column, disaccharide units, to which galectins are expected to bind or not in theory, are shown in green and red colors, respectively. * The number includes Galβ1-3 structure in the β1-3 branch in addition to LacNAc unit in the β1-6 branch.
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specificities of several lectins, monoclonal antibodies or virus capsid proteins (14) (15) (16) (17) (18) (19) (20) (21) . In this mini-review, we present a comprehensive dataset, in tabular form, of the chemical structures of HMOs that have been characterized to date, in order to provide a HMO database as a reference for future research on the sugar-binding specificities, inhibitors and biological functions of galectins.
B. Previous and Newly Proposed Core Structures of HMOs
Structural studies of HMOs began during the 1950's, and by 2009 about 115 structures had been determined by several groups.
Based on the characterized HMOs, a core series of 13 structures, was proposed (shown in black in Table 1 Table 2 ). In this mini-review, we propose that the previous 13 core series can be expanded to 19, which include a new series consisting of iso-lacto-N-neooctaose, novo-lacto-N-neooctaose, para-lacto-N-neooctaose, iso-lacto-N-decaose, and novo-lacto-N-decaose (shown in red in Table 1 ). Lacto-Nnovopentaose I is also included in Table 1 , while this is not a new core unit and is relatively minor in HMOs. In fact, FS-novoLNP I (#159 in Table 2 ) is a sole HMO whose core is lacto-N-novopentaose I. The proposed nomenclatures of novel HMOs are also shown in Table 2 .
C. Possible Biosynthetic Pathway of HMO Core Structures
Based on the recent report by Kobata (2) and the 162 HMOs structures described above, it is possible to suggest biosynthetic pathways of HMOs as shown in Fig. 1 . Here, only 4 common enzymes are used throughout the syntheses: iGnT (1-3 extension), IGnT (1-6 branching), β3Gal-T (type 1 termination), β4Gal-T (type 2 formation). Hereby, 18 core structures of HMOs can be synthesized in a systematic manner. However, an issue remains to be elucidated with respect to the substrate specificity of IGnT (β1-6GlcNAc transferase); i.e., whether this enzyme can transfer GlcNAc even after completion of type 2 LacNAc extension (dashed arrows in Fig. 1 ). GlcNAcβ1-3Lac is a reported substrate for IGnT to form a branched tetrasaccharide, GlcNAc β1-3(GlcNAcβ1-6) Lac, but it is possible that IGnT can substantially transfer GlcNAc to the type 2 LacNAc-extended structure.
In other words, other β1,6N-acetylglucosaminyltransferases, but 
D. Structural Features of HMOs
The following structural units are present in the 162 known 
E. Quantitative Aspects of HMOs
The HMOs listed in Table 2 are not found in equal concentrations. The 13 representative neutral HMOs are 2′-FL (#1 in Table   2 The most significant feature of HMOs is the predominance of type 1 oligosaccharides, which contain Galβ1-3GlcNAc, over type 2 saccharides containing Galβ1-4GlcNAc. The milks of non-human species either contain only type 2 saccharides as in the milks of cow, goat, sheep, pig and horse, or else the type 2 predominates over the type 1 as in some apes (79, 81, 82) . In human milk, LNT and LNFP I, the representative type 1 HMOs, are found at concentrations that are three to four times greater than those of the type 2,
i.e., LNnT and LNFP III.
F. Galectins Bind to Milk Oligosaccharides of Human and Other Mammals
Recently, the group led by Cummings reported that HMOs are possible ligands for endogenous human lectins, such as galectins and DC-SIGN (19, 20) . They conducted comprehensive interaction analysis using a glycan microarray platform of the Consortium for Functional Glycomics (CFG) of USA; i.e., interaction analysis between 247 HMOs (162 were completely characterized, while the remaining 85 are not, but included for the analysis) and human galectin-1, 3, 4, 7, 8, and 9. It provides a powerful approach to obtain broad information about basic properties of lectin-binding specificity.
As described by Iwaki and Hirabayashi (18) and by others 2) When the 6-OH of a non-reducing terminal βGal is substituted with GlcNAc for branching by the action of IGnT.
3) When a Lewis structure is formed by fucosylation to 3-OH of a reducing terminal Glc or GlcNAc (in case of type 1 lactosamine, fucosylation to 4-OH instead).
In any event, modification of the 4-OH of a non-reducing terminal βGal is not permitted.
Other modifications do not necessarily harm galectin binding, and some rather enhance the binding to some galectins. They include fucosylation of 2-OH of a non-reducing terminal βGal, as well as various modifications of 3-OH of a non-reducing terminal βGal (e.g., α2-3Sia, α/β1-3Gal, α1-3GalNAc, and LacNAc extension via β1-3 linkage). These rules work well for galectins not only human but also of other organisms.
It is possible to predict which HMOs can be recognized by galectins, since the above described recognition rules are consistent, and thus applicable to any complex HMO. Table 3 ) and 6′-SL (#107), and
F-SL (#108).
There are many useful milk oligosaccharides other than those of human origin (82) . Supplementary Table 1 
G. Potential Use of Milk Oligosaccharides for the Study of Carbohydrate-binding Specificity of Galectins

I. Recent Studies of the Functions of HMOs
It has been suggested that HMOs, as well as bovine and caprine milk oligosaccharides, have several biological functions;
for example, they act as prebiotics and may have the potential of preventing infection, modulating immunity and to be involved in intestinal maturation. It is also reported that HMOs could prevent necrotizing enterocolitis and activate the brain-gut axis. We refer to a number of reviews related to the biological functions of HMOs It can be predicted that in the near future a variety of HMOs will be utilized as tools to clarify the sugar binding specificities of lectins including galectins, virus capsid proteins, monoclonal antibodies and bacterial toxins, as such information is critical for our understanding of the various biological phenomena controlled by glycans. Not only natural HMOs separated from human milk but also synthetic HMOs should be available as tools for these studies (77) . We emphasize, in addition, that future studies designed to clarify the glycosyltransferases involved in the biosynthesis of HMOs in lactating mammary epithelial cells, and relevant studies relating to the human genome, will be highly advantageous for the applied field as well as basic science.
